Model-based design of chemotherapeutic regimens that account for heterogeneity in leucopoenia

British Journal of Haematology

Volumn 132, Issue 6, 2006, Pages 723-735

  Scholz, Markus ^a,b   Engel, Christoph ^a   Loeffler, Markus ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b Institute for Medical Informatics   (Germany)

Author keywords

Chemotherapy; Clinical trials; Leucopoenia; Mathematical modelling

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; LACTATE DEHYDROGENASE; PREDNISONE; VINCRISTINE;

ARTICLE; BONE MARROW TOXICITY; CALCULATION; DISEASE SEVERITY; DOSE RESPONSE; GENETIC HETEROGENEITY; GRANULOPOIESIS; LEUKOPENIA; MATHEMATICAL MODEL; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTES; HUMANS; LEUKOCYTE COUNT; LEUKOPENIA; LYMPHOMA, NON-HODGKIN; MALE; MATHEMATICS; MIDDLE AGED; MODELS, BIOLOGICAL; PREDNISONE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; VINCRISTINE;

EID: 33644906922     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05957.x     Document Type: Article

References (57)

1. Bender R.A. Castle M.C. Margileth D.A. Oliverio V.T. 1977 The pharmacokinetics of [3H]-vincristine in man Clinical Pharmacology and Therapeutics 22 430 435
2. Bennett C.L. Sinkule J.A. Schilsky R.L. Senekjian E. Choi K.E. 1987 Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer Cancer Research 47 1952 1956
3. Benson A.B. III. Read T.R. Goebel S.L. Koeller J.M. Tormey D.C. 1985 Correlations between leucocyte count and absolute granulocyte count in patients receiving cancer chemotherapy Cancer 56 1350 1355
4. Bergh J. Wiklund T. Erikstein B. Fornander T. Bengtsson N.O. Malmstrom P. Kellokumpu-Lehtinen P. Anker G. Bennmarker H. Wilking N. 1998 Dosage of adjuvant G-CSF (filgrastim)-supported FEC polychemotherapy based on equivalent haematological toxicity in high-risk breast cancer patients. Scandinavian Breast Group, Study SBG 9401 Annals of Oncology 9 403 411
5. Bergh J. Wiklund T. Erikstein B. Lidbrink E. Lindman H. Malmstrom P. Kellokumpu-Lehtinen P. Bengtsson N.O. Soderlund G. Anker G. Wist E. Ottosson S. Salminen E. Ljungman P. Holte H. Nilsson J. Blomqvist C. Wilking N. 2000 Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 Study Lancet 356 1384 1391
6. Blayney D.W. LeBlanc M.L. Grogan T. Gaynor E.R. Chapman R.A. Spiridonidis C.H. Taylor S.A. Bearman S.I. Miller T.P. Fisher R.I. 2003 Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349) Journal of Clinical Oncology 21 2466 2473
7. Blumenthal R.D. Reising A. Leon E. Goldenberg D.M. 2002 Modulation of marrow proliferation and chemosensitivity by tumor-produced cytokines from syngeneic pancreatic tumor lines Clinical Cancer Research 8 1301 1309
8. Bodey G.P. Buckley M. Sathe Y.S. Freireich E.J. 1966 Quantitative relationships between circulating leucocytes and infection in patients with acute leukemia Annals of Internal Medicine 64 328 340
9. Brigden M.L. Mawji K.B. Wilson K.S. Spinelli J.J. 1991 The relationship between the absolute granulocyte count, platelet count and total leucocyte count in cancer chemotherapy patients Clinical and Investigative Medicine. Medecine Clinique et Experimentale 14 395 401
10. Brosteanu O. Hasenclever D. Loeffler M. Diehl V. Group G.H. 2004 Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease Annals of Hematology 83 176 182
11. Busse D. Busch F.W. Bohnenstengel F. Eichelbaum M. Fischer P. Opalinska J. Schumacher K. Schweizer E. Kroemer H.K. 1997 Dose escalation of cyclophosphamide in patients with breast cancer: consequences for pharmacokinetics and metabolism Journal of Clinical Oncology 15 1885 1896
12. Carpenter J.T. Jr. Maddox W.A. Laws H.L. Wirtschafter D.D. Soong S.J. 1982 Favorable factors in the adjuvant therapy of breast cancer Cancer 50 18 23
13. Chatta G.S. Price T.H. Allen R.C. Dale D.C. 1994 Effects of in vivo recombinant methionyl human granulocyte colony-stimulating factor on the neutrophil response and peripheral blood colony-forming cells in healthy young and elderly adult volunteers Blood 84 2923 2929
14. Colijn C. Mackey M.C. 2005a A mathematical model of hematopoiesis: II. Cyclical neutropenia Journal of Theoretical Biology 237 133 146
15. Colijn C. Mackey M.C. 2005b A mathematical model of hematopoiesis: I. Periodic chronic myelogenous leukemia Journal of Theoretical Biology 237 117 132
16. Cortes E.P. Holland J.F. Wang J.J. Sinks L.F. Blom J. Senn H. Bank A. Glidewell O. 1974 Amputation and adriamycin in primary osteosarcoma New England Journal of Medicine 291 998 1000
17. Diehl V. Franklin J. Pfreundschuh M. Lathan B. Paulus U. Hasenclever D. Tesch H. Herrmann R. Dorken B. Muller-Hermelink H.K. Duhmke E. Loeffler M. 2003 Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease New England Journal of Medicine 348 2386 2395
18. Dixon D.O. Neilan B. Jones S.E. Lipschitz D.A. Miller T.P. Grozea P.N. Wilson H.E. 1986 Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience Journal of Clinical Oncology 4 295 305
19. Engel C. Loeffler M. Schmitz S. Tesch H. Diehl V. 2000 Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group (GHSG) Annals of Oncology 11 1105 1114
20. Engel C. Scholz M. Loeffler M. 2004 A computational model of human granulopoiesis to simulate the hematotoxic effects of multicycle polychemotherapy Blood 104 2323 2331
21. Friberg L.E. Henningsson A. Maas H. Nguyen L. Karlsson M.O. 2002 Model of chemotherapy-induced myelosuppression with parameter consistency across drugs Journal of Clinical Oncology 20 4713 4721
22. Gorschluter M. Bohlen H. Hasenclever D. Diehl V. Tesch H. 1995 Serum cytokine levels correlate with clinical parameters in Hodgkin's disease Annals of Oncology 6 477 482
23. Gurney H. 1996 Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative Journal of Clinical Oncology 14 2590 2611
24. Gurney H. 2002 How to calculate the dose of chemotherapy British Journal of Cancer 86 1297 1302
25. Hasenclever D. Loeffler M. Diehl V. 1996 Rationale for dose escalation of first line conventional chemotherapy in advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group Annals of Oncology 7 Suppl. 4 95 98
26. Hasenclever D. Brosteanu O. Gerike T. Loeffler M. 2001 Modelling of chemotherapy: the effective dose approach Annals of Hematology 80 Suppl. 3 B89 94
27. Hortobagyi G.N. 2001 Progress in systemic chemotherapy of primary breast cancer: an overview Journal of the National Cancer Institute. Monographs 30 72 79
28. Horwich A. Sleijfer D.T. Fossa S.D. Kaye S.B. Oliver R.T. Cullen M.H. Mead G.M. de Wit R. de Mulder P.H. Dearnaley D.P. Cook P.A. Sylvester R.J. Stenning S.P. 1997 Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multi-institutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial Journal of Clinical Oncology 15 1844 1852
29. Iyer L. Ratain M.J. 1998 Pharmacogenetics and cancer chemotherapy European Journal of Cancer 34 1493 1499
30. Kloess M. Wunderlich A. Truemper L. Pfreundschuh M. Loeffler M. 2001 Relationship between prognostic factors for therapy and hematotoxicity in aggressive NHL Annals of Hematology 80 Suppl. III B145 B146 (abstract)
31. Kobayashi K. Ratain M.J. 1993 Individualizing dosing of cancer chemotherapy Seminars in Oncology 20 30 42
32. Li F.P. Danahy J. Gelman R. 1984 Utility of differential leucocyte counts in cancer management JAMA 252 1312 1314
33. Liang L.B. Ma Y.W. Zhou X.S. Yang J. Li Y.C. Wang Z. Zhou L.P. Zhang Y.P. Zhao Q.Z. 2003 Selective myelo-protection by MDR1 and MnSOD genes regulated by a specific promoter Zhonghua Zhong Liu Za Zhi 25 17 20
34. Lohrmann H.P. Schreml W. 1982 Cytotoxic drugs and the granulopoietic system Recent Results in Cancer Research 81 1 222
35. von Minckwitz G. Raab G. Caputo A. Schutte M. Hilfrich J. Blohmer J.U. Gerber B. Costa S.D. Merkle E. Eidtmann H. Lampe D. Jackisch C. du Bois A. Kaufmann M. 2005 Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group Journal of Clinical Oncology 23 2676 2685
36. Oken M.M. Creech R.H. Tormey D.C. Horton J. Davis T.E. McFadden E.T. Carbone P.P. 1982 Toxicity and response criteria of the Eastern Cooperative Oncology Group American Journal of Clinical Oncology 5 649 655
37. Ostby I. Kvalheim G. Rusten L.S. Grottum P. 2004 Mathematical modeling of granulocyte reconstitution after high-dose chemotherapy with stem cell support: effect of post-transplant G-CSF treatment Journal of Theoretical Biology 231 69 83
38. Pettengell R. Gurney H. Radford J.A. Deakin D.P. James R. Wilkinson P.M. Kane K. Bentley J. Crowther D. 1992 Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial Blood 80 1430 1436
39. Pfreundschuh M. Trumper L. Kloess M. Schmits R. Feller A.C. Rube C. Rudolph C. Reiser M. Hossfeld D.K. Eimermacher H. Hasenclever D. Schmitz N. Loeffler M. 2004a Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL Blood 104 634 641
40. Pfreundschuh M. Trumper L. Kloess M. Schmits R. Feller A.C. Rudolph C. Reiser M. Hossfeld D.K. Metzner B. Hasenclever D. Schmitz N. Glass B. Rube C. Loeffler M. 2004b Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL Blood 104 626 633
41. Poikonen P. Saarto T. Lundin J. Joensuu H. Blomqvist C. 1999 Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF British Journal of Cancer 80 1763 1766
42. Rankin E.M. Mill L. Kaye S.B. Atkinson R. Cassidy L. Cordiner J. Cruickshank D. Davis J. Duncan I.D. Fullerton W. Habeshaw T. Kennedy J. Kennedy R. Kitchener H. MacLean A. Paul J. Reed N. Sarker T. Soukop M. Swapp G.H. Symonds R.P. 1992 A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer British Journal of Cancer 65 275 281
43. Rechenberg I. 1984 The evolution strategy: a mathematical model of Darwinian evolution Springer Series in Synergetics 22 122 132
44. Rechenberg I. 1994 Evolutionsstrategie '94 Frommann-Holzboog
45. Rushing D.A. Raber S.R. Rodvold K.A. Piscitelli S.C. Plank G.S. Tewksbury D.A. 1994 The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer Cancer 74 834 841
46. Sandstrom M. Lindman H. Nygren P. Lidbrink E. Bergh J. Karlsson M.O. 2005 Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients Journal of Clinical Oncology 23 413 421
47. Scholz M. Engel C. Loeffler M. 2004 Modelling human granulopoiesis under poly-chemotherapy with G-CSF support Journal of Mathematical Biology 50 397 439
48. Schwefel H.P. 1984 Evolution strategies: a family of nonlinear optimization techniques based on imitating some principles of organic evolution Annales of Operational Research 1 165 167
49. Shipp M.A. Neuberg D. Janicek M. Canellos G.P. Shulman L.N. 1995 High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study Journal of Clinical Oncology 13 2916 2923
50. Sinkule J.A. 1984 Etoposide: a semisynthetic epipodophyllotoxin. Chemistry, pharmacology, pharmacokinetics, adverse effects and use as an antineoplastic agent Pharmacotherapy 4 61 73
51. Sulkes A. Collins J.M. 1987 Reappraisal of some dosage adjustment guidelines Cancer Treatment Reports 71 229 233
52. Tesch H. Diehl V. Lathan B. Hasenclever D. Sieber M. Ruffer U. Engert A. Franklin J. Pfreundschuh M. Schalk K.P. Schwieder G. Wulf G. Dolken G. Worst P. Koch P. Schmitz N. Bruntsch U. Tirier C. Muller U. Loeffler M. 1998 Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group Blood 92 4560 4567
53. The International Non-Hodgkin's Lymphoma Prognostic Factors Project 1993 A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project New England Journal of Medicine 329 987 994
54. Trillet-Lenoir V. Green J.A. Manegold C. Von Pawel J. Gatzemeier U. Lebeau B. Depierre A. Johnson P. Decoster G. Matcham J. Ewen C. 1995 Recombinant granulocyte colony stimulating factor in the treatment of small cell lung cancer: a long-term follow-up European Journal of Cancer 31A 2115 2116
55. Vainstein V. Ginosar Y. Shoham M. Ranmar D.O. Ianovski A. Agur Z. 2005 The complex effect of granulocyte colony-stimulating factor on human granulopoiesis analyzed by a new physiologically-based mathematical model Journal of Theoretical Biology 234 311 327
56. Wilson W.H. Grossbard M.L. Pittaluga S. Cole D. Pearson D. Drbohlav N. Steinberg S.M. Little R.F. Janik J. Gutierrez M. Raffeld M. Staudt L. Cheson B.D. Longo D.L. Harris N. Jaffe E.S. Chabner B.A. Wittes R. Balis F. 2002 Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy Blood 99 2685 2693
57. Wunderlich A. Kloess M. Reiser M. Rudolph C. Truemper L. Bittner S. Schmalenberg H. Schmits R. Pfreundschuh M. Loeffler M. 2003 Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) Annals of Oncology 14 881 893